SARS and MERS: recent insights into emerging coronaviruses (Q30249325)

13 June 2017

3 references

13 July 2022

22 October 2022

SARS and MERS: recent insights into emerging coronaviruses (English)

1 reference

13 June 2017

0 references

1 reference

Emmie de Wit

1

0 references

Darryl Falzarano

series ordinal

3

object named as

Darryl Falzarano

1 reference

13 June 2017

Neeltje van Doremalen

series ordinal

2

object named as

Neeltje van Doremalen

1 reference

13 June 2017

4

Vincent J Munster

1 reference

13 June 2017

language of work or name

English

0 references

publication date

27 June 2016

1 reference

13 June 2017

1 August 2016

2 references

13 July 2022

22 October 2022

12

1 reference

Nature Reviews Microbiology

inferred from page(s)

published in

3 references

13 June 2017

13 July 2022

22 October 2022

14

1 reference

13 June 2017

8

1 reference

13 June 2017

523-534

1 reference

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003.

13 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A major outbreak of severe acute respiratory syndrome in Hong Kong

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A novel coronavirus associated with severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Coronavirus as a possible cause of severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

SARS-CoV infection in a restaurant from palm civet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Patient with new strain of coronavirus is treated in intensive care at London hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Nidovirus transcription: how to make sense...?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Coronaviruses post-SARS: update on replication and pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Coronaviruses: an overview of their replication and pathogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

31 March 2020

Review of bats and SARS

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Evidence for camel-to-human transmission of MERS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

MERS coronavirus in dromedary camel herd, Saudi Arabia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Transmission of Middle East Respiratory Syndrome Coronavirus Infections in Healthcare Settings, Abu Dhabi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South Korea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East Respiratory Syndrome Coronavirus Superspreading Event Involving 81 Persons, Korea 2015.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

MERS, SARS, and Ebola: The Role of Super-Spreaders in Infectious Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Angiotensin-converting enzyme 2 protects from severe acute lung failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Biomarkers in acute respiratory distress syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

The mercurial nature of neutrophils: still an enigma in ARDS?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

SARS-CoV virus-host interactions and comparative etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of formalin-fixed paraffin-embedded tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Rapid generation of a mouse model for Middle East respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

In vitro reconstitution of SARS-coronavirus mRNA cap methylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2'-o-methyltransferase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor of RNA Silencing in Mammalian Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East Respiratory Syndrome Coronavirus nsp1 Inhibits Host Gene Expression by Selectively Targeting mRNAs Transcribed in the Nucleus while Sparing mRNAs of Cytoplasmic Origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

MAVS-mediated apoptosis and its inhibition by viral proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Mechanisms of action of ribavirin against distinct viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Identification of severe acute respiratory syndrome in Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Development of a standard treatment protocol for severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A cluster of cases of severe acute respiratory syndrome in Hong Kong.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East Respiratory Syndrome-Coronavirus Infection: A Case Report of Serial Computed Tomographic Findings in a Young Male Patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Clinical Implications of 5 Cases of Middle East Respiratory Syndrome Coronavirus Infection in a South Korean Outbreak

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Protease inhibitors targeting coronavirus and filovirus entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A decade after SARS: strategies for controlling emerging coronaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

SARS vaccines: where are we?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East respiratory syndrome: current status and future prospects for vaccine development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Evaluation of candidate vaccine approaches for MERS-CoV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Immune efficacy of first and repeat trivalent influenza vaccine in healthy subjects and hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Middle East respiratory syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Mortality Risk Factors for Middle East Respiratory Syndrome Outbreak, South Korea, 2015.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Animal models for SARS and MERS coronaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Replication and shedding of MERS-CoV in Jamaican fruit bats (Artibeus jamaicensis)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Bats are natural reservoirs of SARS-like coronaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

SARS-like WIV1-CoV poised for human emergence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2016.81

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.

31 March 2020

1 reference

12 December 2020

Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014

1 reference

12 December 2020

The role of C5a in acute lung injury induced by highly pathogenic viral infections

1 reference

12 December 2020

Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation

1 reference

12 December 2020

Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study.

1 reference

12 December 2020

Clinical analysis of the first patient with imported Middle East respiratory syndrome in China

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRMICRO.2016.81

1 reference

Dimensions Publication ID

13 June 2017

0 references

0 references

0 references

1 reference